Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS
Authors
Keywords
Luminal Breast Cancer, Complete Tumor Regression, Exact Confidence Interval, ERneg Patient, Immune Response Rate
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 20, Issue 10, Pages 3233-3239
Publisher
Springer Nature
Online
2013-07-13
DOI
10.1245/s10434-013-3119-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab
- (2013) S. Ithimakin et al. CANCER RESEARCH
- Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers
- (2012) Rita Nahta et al. BREAST CANCER RESEARCH AND TREATMENT
- HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
- (2012) Anupama Sharma et al. CANCER
- Dendritic cell-based vaccines: barriers and opportunities
- (2012) Jessica A Cintolo et al. Future Oncology
- Clinical trial results of the HER-2/neu(E75) vaccine to prevent breast cancer recurrence in high-risk patients
- (2011) Elizabeth A. Mittendorf et al. CANCER
- Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer
- (2011) Allan Hackshaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Recent Developments in Cancer Vaccines
- (2011) K. Palucka et al. JOURNAL OF IMMUNOLOGY
- A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer
- (2011) Gary K. Koski et al. JOURNAL OF IMMUNOTHERAPY
- The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease
- (2011) Shuko Harada et al. JOURNAL OF SURGICAL ONCOLOGY
- Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
- (2010) K. M. O'Brien et al. CLINICAL CANCER RESEARCH
- HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer
- (2009) R. E. Roses et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen
- (2009) Gauri Sabnis et al. CANCER RESEARCH
- The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2009) L. C. Benavides et al. CLINICAL CANCER RESEARCH
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
- (2009) E. A. Mittendorf et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started